Marc Darrow, MD JD
A reader asks: “I am 72 years old. Is my blood young enough to generate therapeutic PRP?”
Being 72 does not automatically make you too old to have PRP prepared from your own blood or to be considered for treatment. But producing a platelet concentrate and knowing that it will provide a therapeutic benefit are two different questions.
My first concern would be what we are treating. Is the pain coming from knee arthritis, a tendon, a joint capsule, or another structure? Then I would consider the condition of that tissue, your health and medications, and the preparation being proposed. Age belongs in that assessment, but it should not replace it.
What does it mean to “generate therapeutic PRP”?
PRP, or platelet-rich plasma, is prepared by processing a sample of your blood to concentrate platelets in a portion of the plasma. Platelets contain and release signaling molecules involved in inflammation and tissue responses. PRP is not a stem-cell injection.
“Therapeutic” should describe a meaningful clinical benefit, such as reduced pain or improved function. It is not something we can guarantee simply because the processed sample contains more platelets than the original blood.
There are three separate questions: Can a suitable preparation be obtained? Is there evidence for using that preparation for your diagnosis? And will you personally respond? A blood count may help with the first question, but it cannot answer all three.
Does aging change platelet count or PRP composition?
It can. A 2025 observational study of 384 patients found a small negative correlation between age and circulating platelet count. The relationship was weak, which means age alone could not reliably tell us an individual’s platelet count. The study did not test orthopedic treatment outcomes. (2)
A 2024 laboratory study compared PRP from six younger and six older volunteers. Researchers found differences in protein profiles, including proteins associated with inflammation-related pathways and cell activity. This was a small composition study, not evidence that every older patient’s PRP is ineffective. (3)
These findings support individual assessment and better characterization of PRP. They do not establish a cutoff at 60, 70, or 72 years.
What about studies suggesting younger platelets work better?
A 2023 experimental study compared PRP from younger donors aged 18–35 with PRP from donors aged 65 or older. Younger-donor PRP produced more favorable results in human cartilage-cell experiments and aged mice. Older-donor PRP did not produce the same benefits in those experiments. (4)
This is important biological research, but it was not a randomized treatment trial in 72-year-old patients. Laboratory cartilage markers and mouse cartilage changes cannot directly predict your pain relief, walking ability, or response to treatment.
There are also two sides to the question: the characteristics of the preparation and the ability of the tissue receiving it to respond. An older arthritic joint may differ from a younger injured tendon in many ways beyond the age of the platelets.
What do clinical studies show in older patients?
Most age-related orthopedic PRP research involves knee osteoarthritis. Those findings are useful examples, but they should not be transferred automatically to a shoulder tear, hip arthritis, or spinal pain.
A study including patients over 60 found improvement across age groups
A 2023 prospective study treated 65 people with moderate knee osteoarthritis using three PRP injections. Twenty-three were older than 60. Symptoms improved across the groups, and researchers did not find significant differences between the age subgroups. However, there was no placebo group, the subgroups were small, and “over 60” is not a specific analysis of people aged 72. (5)
The study supports avoiding a simple assumption that older age prevents improvement. It does not prove that PRP works equally well at all ages.
A newer cohort included patients up to age 76
A prospective knee-arthritis study published online in 2025 and in print in 2026 evaluated a leukocyte-poor PRP preparation called autologous conditioned plasma. Forty patients with 49 knees completed follow-up; ages ranged from 35 to 76. Older age and higher platelet concentration were associated with better follow-up function scores in the researchers’ model. (6)
This does not establish that older patients respond better. It was a small, uncontrolled study with a relatively young average age. It does show why laboratory concerns about aging should not be treated as a reliable prediction of clinical failure.
Advanced arthritis changes expectations
A randomized study enrolled 75 people with advanced knee arthritis and compared a single PRP injection with corticosteroid. Most outcomes did not differ significantly between groups. In the subgroup aged 67 or older, the researchers reported similar results with the two treatments. (7)
This does not mean older platelets are useless. It means PRP should not be assumed to outperform another injection simply because it is described as regenerative. The severity and nature of the joint problem still matter.
PRP does not work for every patient—even in a well-conducted trial
The RESTORE trial randomized 288 adults aged 50 or older with mild-to-moderate knee osteoarthritis to PRP or saline injections. At 12 months, PRP did not provide a statistically significant advantage in the primary pain or cartilage-volume outcomes. (8)
That trial was not designed to establish a cutoff at age 72. It is relevant because it separates two questions: being able to prepare PRP and demonstrating that a particular treatment helps.
Symptom improvement also should not automatically be described as cartilage regrowth. A useful discussion identifies what outcome the evidence supports and how closely the study matches the proposed treatment.
What matters besides age?
The diagnosis and the condition of the tissue
Before discussing platelet quality, we need to identify the structure causing symptoms. The amount of arthritis, a substantial tear, mechanical instability, nerve compression, or another diagnosis may change what is realistic. An injection should have a defined target.
Your blood count and medical history
A blood count may be appropriate when the history raises questions about platelet numbers, anemia, or another blood disorder. A normal platelet count does not guarantee that a finished PRP preparation will work. An abnormal result may require further assessment rather than an assumption based on age.
A 2025 formal consensus addressed PRP use in people with infectious, oncologic, and hematologic conditions. It emphasized that these conditions require specific assessment. Its recommendations are expert guidance, not a test that can predict treatment success. (9)
The preparation and proposed treatment plan
PRP varies in platelet concentration, white-cell and red-cell content, volume, and processing method. The total platelet dose depends on both concentration and injected volume. A higher concentration is not automatically better for every tissue, and a universal ideal dose has not been established. (1)
It is reasonable to ask how the preparation is characterized and why it was selected for your condition. A claim that “more platelets will overcome your age” goes beyond what those measurements can establish.
Your medications
Tell the treating clinician about aspirin, other antiplatelet medicines, anticoagulants, anti-inflammatory medicines, and supplements. Their relevance depends on the medicine, the planned procedure, and your reason for taking it.
Do not stop a medication prescribed to prevent a heart attack, stroke, or blood clot on your own. Any change should be coordinated with the prescribing clinician. Medication review is part of planning care; it is not a reason to make a blanket recommendation to stop treatment before PRP.
Can a blood test tell me whether my PRP will work?
Routine tests can provide useful information about platelet numbers and other aspects of health. They cannot reliably certify that PRP will be “therapeutic” for a particular painful joint or tendon.
Preparation measurements and laboratory research improve our understanding, but clinical response still depends on the diagnosis, the treated tissue, and the intervention. A result should not be presented as a guarantee of pain relief.
What would I tell this 72-year-old reader?
You are not automatically too old to be considered for PRP. Your age alone does not establish that your platelets are incapable of contributing to a useful treatment.
The next step is to clarify what hurts, establish the diagnosis, review your health and medicines, and discuss the evidence for the particular preparation and injection target. If treatment is reasonable, we should agree on measurable goals and when to reassess if it is not helping.
My question would be less “Are you young enough?” and more “Is PRP an appropriate treatment for the problem you have, with a realistic chance of improving the activities that matter to you?”
Related reading
- What is platelet-rich plasma therapy?
- Shoulder pain, rotator cuff tears, and return to golf
- Frequently asked questions about treatment
References
1 Hurley ET, Sherman SL, Stokes DJ, Rodeo SA, Shapiro SA, Mautner K, Buford DA, Dragoo JL, Mandelbaum BR, Zaslav KR, Cole BJ, Frank RM, Members of the Biologics Association. Experts Achieve Consensus on a Majority of Statements Regarding Platelet-Rich Plasma Treatments for Treatment of Musculoskeletal Pathology. Arthroscopy. 2024;40(2):470-477.e1. doi:10.1016/j.arthro.2023.08.020.
2 Sánchez-Pérez A, Palma-Sánchez A, Jornet-García A, Moya-Villaescusa MJ, Montoya-Carralero JM. Influence of age and sex on platelet count: Implications for optimizing growth factor-rich plasma preparation. J Clin Exp Dent. 2025;17(11):e1292-e1297. doi:10.4317/jced.63137.
3 Jiang Z, Huang C, Guo E, Zhu X, Li N, Huang Y, Wang P, Shan H, Yin Y, Wang H, Huang L, Han Z, Ouyang K, Sun L. Platelet-Rich Plasma in Young and Elderly Humans Exhibits a Different Proteomic Profile. J Proteome Res. 2024;23(5):1788-1800. doi:10.1021/acs.jproteome.4c00030.
4 Chowdhary K, Sahu A, Iijima H, Shinde S, Borg-Stein J, Ambrosio F. Aging Affects the Efficacy of Platelet-Rich Plasma Treatment for Osteoarthritis. Am J Phys Med Rehabil. 2023;102(7):597-604. doi:10.1097/phm.0000000000002161.
5 Saraf A, Hussain A, Singhal A, Arora V, Bishnoi S. Do age, gender, BMI and disease duration influence the clinical outcomes in patients of knee osteoarthritis treated with serial injections of autologous platelet rich plasma?. J Clin Orthop Trauma. 2023;43:102226. doi:10.1016/j.jcot.2023.102226.
6 Selim A, Lan T, Hulme C, Williams M, Perry J, Gallacher P, Jermin P, Wright K. Clinical and Cellular Predictors of Outcomes in Autologous Conditioned Plasma Therapy for Knee Osteoarthritis: A Prospective Cohort Study. Cartilage. 2026;17(2):123-132. doi:10.1177/19476035251323376.
7 Joshi Jubert N, Rodríguez L, Reverté-Vinaixa MM, Navarro A. Platelet-Rich Plasma Injections for Advanced Knee Osteoarthritis: A Prospective, Randomized, Double-Blinded Clinical Trial. Orthop J Sports Med. 2017;5(2):2325967116689386. doi:10.1177/2325967116689386.
8 Bennell KL, Paterson KL, Metcalf BR, Duong V, Eyles J, Kasza J, Wang Y, Cicuttini F, Buchbinder R, Forbes A, Harris A, Yu SP, Connell D, Linklater J, Wang BH, Oo WM, Hunter DJ. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415.
9 Eymard F, Louati K, Noel É, Abouqal R, Adam P, Allali F, Antherieu G, Caers J, Cognasse F, Collado H, Darrieutort-Laffite C, Frère C, Frey A, Gavillet M, Gremeaux V, Heiblig M, Jerusalem G, Joly C, Kaux JF, Lamontagne M, Leclerc M, Léonard P, Lepeule R, Lopez-Trabada-Ataz D, Magalon J, Michel F, Ornetti P, Oury C, Pons-Tostivint E, Real F, Robert G, Sanchez M, Silvestre A, Bard H. Indications and contraindications to platelet-rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections). Knee Surg Sports Traumatol Arthrosc. 2025;33(6):2293-2306. doi:10.1002/ksa.12682.





